AAX Biotech is developing new technologies to improve antibodies for therapy.
AAX Biotech is developing new technologies to improve antibodies for therapy
AAX Biotech is developing new technologies to improve antibodies for therapy, the fastest growing segment in pharmaceuticals for more than 20 years. Seqitope is a new high-resolution, fast and efficient method for determining exactly where antibodies bind to the target protein, which accelerates the development of new antibodies. With Opti-mAb, we have developed a general method to stabilize antibodies, of great value in new cell-based cancer treatments such as CAR-T, but also for therapeutic bi-specific antibodies, and in diagnostics. In addition, a more efficient production, a more homogeneous product and fewer side effects are obtained during clinical use.
Contact: info@aaxbiotech.com
Read about AAX Biotech here.